Epidemiology of Sepsis in China
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02448472|
Recruitment Status : Completed
First Posted : May 19, 2015
Last Update Posted : February 17, 2016
|Condition or disease||Intervention/treatment|
|Sepsis||Other: Observational study, none intervention|
Sepsis,especially severe sepsis is a major cause of admission to the intensive care unit (ICU) and death. In USA, the incidence of sepsis is about 3/1000 population. However, the incidence of sepsis varies among different clinic trails. Between 6 and 54% of patients admitted to ICUs have severe sepsis and the mortality rate for these patients varies from 20 to 60%. There is no exactly results of incidence of sepsis in China.
In addition, clinician empirical select antibiotic according to the epidemiology of sepsis, however, the etiology of sepsis is various in different studies. In EPIC II study, the organisms of sepsis include Gram-positive microorganisms (69.8%),Gram-negative microorganisms(62.2%) and fungi (17%). In China, the MDRO is much higher than western country. In contrast to EPIC II study, one study in China showed that the organisms of sepsis include Gram-positive microorganisms (14.5%),Gram-negative microorganisms(62.5%) and fungi (2.2%). Therefore, it is necessary to conduct a study about epidemiology of sepsis in China.
|Study Type :||Observational|
|Estimated Enrollment :||2000 participants|
|Official Title:||Chinese Epidemiological Study of Severe Sepsis.(CHESS Study)|
|Study Start Date :||November 2015|
|Primary Completion Date :||December 2015|
|Study Completion Date :||January 2016|
- Incidence [ Time Frame: Patients will be assessed up to 90 days ]
- Mortality [ Time Frame: Sepsis and severe sepsis patients will be assessed up to 90 days ]
- etiology [ Time Frame: The pathogen of sepsis will be assessed up to 90 days ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02448472
|Zhongda hospital, Southeast University|
|Nanjing, Jiangsu, China, 210009|
|Study Director:||Yang Yi, Ph.D.||Zhongda hospital, Southeast University|